Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab for Pain and Physical Function in MPS I, II, and VI
NCT02437253Phase 2Completed
- Sponsor
- The Lundquist Institute
- Start
- May 2015
- Primary completion
- Jul 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of adalimumab in mucopolysaccharidosis type I, mucopolysaccharidosis type II, mucopolysaccharidosis type VI, sponsored by The Lundquist Institute. Started May 2015; status: completed.
02
Drugs
03
Conditions
mucopolysaccharidosis type Imucopolysaccharidosis type IImucopolysaccharidosis type VI
Beyond the preview
Go deeper on NCT02437253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02437253.